Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Director · Pres. & Chief Exec. Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,064 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 8,165 · Balance 29,644 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. Row 2 · 2026-10-05 · Sale · Disposed 8,580 · Balance 21,064 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold Descendants 2020 Trust | 8,038 |
Reported balance
After 2026-10-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-05 · Sale · Disposed 3,198 · Balance 8,038 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. |
| Common StockSEC Table I · non-derivative | IndirectBy Derek Maetzold 2020 Irrevocable Trust | 6,832 |
Reported balance
After 2026-10-05 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-05 · Sale · Disposed 2,718 · Balance 6,832 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.39 · Expires 2028-05-09 | Direct | 0 |
Reported balance
After 2026-10-05 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-10-05 · Exercise / conversion · Disposed 8,165 · Balance 0 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F13: The shares subject to the option are fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,256 F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 11,256 F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 11,256 F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 11,256 F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 6 | 11,963 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 11,963 F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 7 | 27,862 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 27,862 F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 8 | 40,935 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 40,935 F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectDJM Grantor Retained Annuity Trust No. 9 | 23,216 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 23,216 F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.
F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.
F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.
F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary.
F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary.
F13: The shares subject to the option are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 21, 2020 Filed Oct 22, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 200 | $47.34 | $9,467.00 |
DisclosureSEC source: 0001447362-20-000245 · wf-form4_160339714746734.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,414,148 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $47.040 to $47.610, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 100 | $50.09 | $5,009.00 |
DisclosureSEC source: 0001447362-20-000245 · wf-form4_160339714746734.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,414,348 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 900 | $49.61 | $44,645.40 |
DisclosureSEC source: 0001447362-20-000245 · wf-form4_160339714746734.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,414,448 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $49.060 to $50.030, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 02, 2020 Filed Oct 5, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 200 | $52.22 | $10,443.40 |
DisclosureSEC source: 0001447362-20-000228 · wf-form4_160192830937248.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,415,348 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $52.210 to $52.310, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 02, 2020 Filed Oct 5, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,800 | $51.64 | $299,517.80 |
DisclosureSEC source: 0001447362-20-000228 · wf-form4_160192830937248.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,415,548 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $51.140 to $52.125, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,000 | $51.68 | $103,360.00 |
DisclosureSEC source: 0001447362-20-000228 · wf-form4_160192830937248.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,421,348 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $51.270 to $52.050, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 646 | $52.07 | $33,633.99 |
DisclosureSEC source: 0001447362-20-000228 · wf-form4_160192830937248.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,423,348 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $51.970 to $52.130, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 9,994 | $51.59 | $515,550.48 |
DisclosureSEC source: 0001447362-20-000228 · wf-form4_160192830937248.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,423,994 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.940 to $51.920, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 20:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 362 | $52.14 | $18,872.87 |
DisclosureSEC source: 0001447362-20-000225 · wf-form4_160097785726941.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,433,988 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $52.110 to $52.185, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 20:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,554 | $51.59 | $131,763.41 |
DisclosureSEC source: 0001447362-20-000225 · wf-form4_160097785726941.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,434,350 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $51.105 to $52.100, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 20:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,084 | $50.55 | $155,902.37 |
DisclosureSEC source: 0001447362-20-000225 · wf-form4_160097785726941.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,436,904 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $50.090 to $51.080, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 20:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,048 | $51.75 | $209,488.05 |
DisclosureSEC source: 0001447362-20-000225 · wf-form4_160097785726941.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,439,988 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $51.610 to $52.120, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 20:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 8,552 | $51.32 | $438,845.88 |
DisclosureSEC source: 0001447362-20-000225 · wf-form4_160097785726941.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,444,036 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $50.610 to $51.600, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 20:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 9,023 | $51.71 | $466,552.26 |
DisclosureSEC source: 0001447362-20-000225 · wf-form4_160097785726941.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,452,588 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $51.600 to $52.400, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 20:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 14,537 | $51.32 | $745,995.23 |
DisclosureSEC source: 0001447362-20-000225 · wf-form4_160097785726941.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,461,611 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.600 to $51.590, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 200 | $49.94 | $9,987.60 |
DisclosureSEC source: 0001447362-20-000219 · wf-form4_160011420043026.xml · nonDerivative · entry 9 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,476,148 F5 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F11 · price: This transaction was executed in multiple trades at prices ranging from $49.890 to $49.985, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 900 | $48.70 | $43,830.90 |
DisclosureSEC source: 0001447362-20-000219 · wf-form4_160011420043026.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,476,348 F5 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F10 · price: This transaction was executed in multiple trades at prices ranging from $48.500 to $49.490, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,935 | $49.58 | $343,837.30 |
DisclosureSEC source: 0001447362-20-000219 · wf-form4_160011420043026.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,477,248 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $49.120 to $50.090, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,741 | $48.65 | $230,663.87 |
DisclosureSEC source: 0001447362-20-000219 · wf-form4_160011420043026.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,484,183 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $48.080 to $49.040, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,700 | $50.07 | $85,119.00 |
DisclosureSEC source: 0001447362-20-000219 · wf-form4_160011420043026.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,488,924 F5 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $49.840 to $50.320, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 600 | $48.98 | $29,386.20 |
DisclosureSEC source: 0001447362-20-000219 · wf-form4_160011420043026.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,490,624 F5 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $48.690 to $49.405, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,405 | $50.40 | $70,813.41 |
DisclosureSEC source: 0001447362-20-000219 · wf-form4_160011420043026.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,491,224 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $50.230 to $50.710, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 24,204 | $49.82 | $1,205,770.67 |
DisclosureSEC source: 0001447362-20-000219 · wf-form4_160011420043026.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,492,629 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.230 to $50.220, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 14,015 | $48.79 | $683,763.82 |
DisclosureSEC source: 0001447362-20-000219 · wf-form4_160011420043026.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,516,833 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.230 to $49.220, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,000 | $43.20 | $43,200.00 |
DisclosureSEC source: 0001447362-20-000177 · wf-form4_159786754776305.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,530,848 F5 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $42.97 to $43.45, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 100 | $43.67 | $4,367.00 |
DisclosureSEC source: 0001447362-20-000177 · wf-form4_159786754776305.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,531,848 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 9,900 | $43.14 | $427,086.00 |
DisclosureSEC source: 0001447362-20-000177 · wf-form4_159786754776305.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,531,948 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $42.65 to $43.58, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 400 | $43.60 | $17,440.00 |
DisclosureSEC source: 0001447362-20-000177 · wf-form4_159786754776305.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541,848 F5 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $43.47 to $43.74, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 600 | $42.39 | $25,434.00 |
DisclosureSEC source: 0001447362-20-000177 · wf-form4_159786754776305.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,542,248 F5 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $42.04 to $42.79, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,000 | $43.43 | $86,860.00 |
DisclosureSEC source: 0001447362-20-000177 · wf-form4_159786754776305.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,542,848 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $42.96 to $43.74, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,000 | $42.40 | $212,000.00 |
DisclosureSEC source: 0001447362-20-000177 · wf-form4_159786754776305.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,544,848 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $41.94 to $42.92, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 500 | $40.95 | $20,475.00 |
DisclosureSEC source: 0001447362-20-000177 · wf-form4_159786754776305.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,549,848 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.76 to $41.47, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:09 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,000 | $40.91 | $40,909.00 |
DisclosureSEC source: 0001447362-20-000175 · wf-form4_159743570029800.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,550,348 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $40.690 to $41.110, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:09 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 200 | $41.70 | $8,340.00 |
DisclosureSEC source: 0001447362-20-000175 · wf-form4_159743570029800.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,551,348 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:09 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 7,300 | $40.97 | $299,102.90 |
DisclosureSEC source: 0001447362-20-000175 · wf-form4_159743570029800.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,551,548 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $40.670 to $41.635, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:09 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,200 | $41.90 | $175,992.60 |
DisclosureSEC source: 0001447362-20-000175 · wf-form4_159743570029800.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,558,848 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $41.520 to $42.240, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:09 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 800 | $40.30 | $32,237.60 |
DisclosureSEC source: 0001447362-20-000175 · wf-form4_159743570029800.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,563,048 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.940 to $40.765, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2020 Filed Aug 8, 2020 00:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,000 | $41.28 | $41,281.00 |
DisclosureSEC source: 0001447362-20-000161 · wf-form4_159684505354964.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,563,848 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $40.835 to $41.760, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2020 Filed Aug 8, 2020 00:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 800 | $42.00 | $33,598.40 |
DisclosureSEC source: 0001447362-20-000161 · wf-form4_159684505354964.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,564,848 F3 · kind: These transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $41.940 to $42.050, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2020 Filed Aug 8, 2020 00:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,700 | $41.29 | $276,649.70 |
DisclosureSEC source: 0001447362-20-000161 · wf-form4_159684505354964.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,565,648 F3 · kind: These transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $40.920 to $41.880, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 05, 2020 Filed Aug 8, 2020 00:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,000 | $41.67 | $208,360.00 |
DisclosureSEC source: 0001447362-20-000161 · wf-form4_159684505354964.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,572,348 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $41.160 to $42.100, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 20:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,290 | $39.86 | $91,279.40 |
DisclosureSEC source: 0001447362-20-000153 · wf-form4_159553453081023.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,577,348 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $39.580 to $40.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 20:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,710 | $39.32 | $106,554.49 |
DisclosureSEC source: 0001447362-20-000153 · wf-form4_159553453081023.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,579,638 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $38.580 to $39.570, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 600 | $42.30 | $25,377.00 |
DisclosureSEC source: 0001447362-20-000153 · wf-form4_159553453081023.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,582,348 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $41.880 to $42.475, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 400 | $40.89 | $16,357.20 |
DisclosureSEC source: 0001447362-20-000153 · wf-form4_159553453081023.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,582,948 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $40.720 to $41.350, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 100 | $42.78 | $4,278.00 |
DisclosureSEC source: 0001447362-20-000153 · wf-form4_159553453081023.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,583,348 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,270 | $42.34 | $180,778.99 |
DisclosureSEC source: 0001447362-20-000153 · wf-form4_159553453081023.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,583,448 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $41.740 to $42.730, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,630 | $41.12 | $67,032.12 |
DisclosureSEC source: 0001447362-20-000153 · wf-form4_159553453081023.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,587,718 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.720 to $41.710, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 20:34 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,992 | $44.87 | $134,251.04 |
DisclosureSEC source: 0001447362-20-000148 · wf-form4_159493167583676.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,589,348 F5 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F10 · price: This transaction was executed in multiple trades at prices ranging from $44.59 to $45.21, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 20:34 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,008 | $44.30 | $88,954.40 |
DisclosureSEC source: 0001447362-20-000148 · wf-form4_159493167583676.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,592,340 F5 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $43.58 to $44.57, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.